The interferon system in patients with malignant disease.
Since the interferon (IFN) system involves both IFN producing and IFN responding cells, it is possible to study separately these phenomena, relating them to disease entities as well as to response to therapy. Numerous studies in animals and man suggest effectiveness of IFN and IFN inducer therapy in cancer. However, the competency of the various components of the endogenous IFN system in malignancy has received little attention. These studies show that in malignancy there may be (1) a high incidence of elevated blood levels of IFN; (2) a deficient response of peripheral blood mononuclear cells to endogenous and exogenous IFN; and (3) increased uninduced in vitro IFN production by these cells. These findings indicate that cancer patients are equipped with the ability to produce IFN and suggest that it may be the deficient response of their cells to IFN that plays a role in the development and progression of the disease. Furthermore, the finding of increased spontaneous "uninduced" production of IFN by cells from cancer patients suggest the possibility of an intracellular inducer such as found in persistently virus-infected cells.
D018219:Histiocytoma, Benign Fibrous / Q000097:blood*; D006801:Humans; D007372:Interferons / Q000097:blood* / Q000494:pharmacology; D007938:Leukemia / Q000097:blood*; D008223:Lymphoma / Q000097:blood*; D009000:Monocytes / Q000378:metabolism*; D010835:Phytohemagglutinins / Q000494:pharmacology; D011070:Poly I-C / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects
D010835:Phytohemagglutinins; D007372:Interferons; D011070:Poly I-C